Champions Total Revenue from 2010 to 2024

CSBR Stock  USD 4.55  0.28  6.56%   
Champions Oncology Total Revenue yearly trend continues to be relatively stable with very little volatility. Total Revenue is likely to grow to about 52.7 M this year. Total Revenue is the total amount of income generated by the sale of goods or services related to Champions Oncology's primary operations. View All Fundamentals
 
Total Revenue  
First Reported
1995-10-31
Previous Quarter
14 M
Current Value
14.1 M
Quarterly Volatility
4.2 M
 
Dot-com Bubble
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Champions Oncology financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Champions Oncology's main balance sheet or income statement drivers, such as Depreciation And Amortization of 2 M, Interest Expense of 38.3 K or Selling General Administrative of 11.6 M, as well as many indicators such as Price To Sales Ratio of 1.24, Dividend Yield of 0.0033 or Days Sales Outstanding of 72.79. Champions financial statements analysis is a perfect complement when working with Champions Oncology Valuation or Volatility modules.
  
Check out the analysis of Champions Oncology Correlation against competitors.
To learn how to invest in Champions Stock, please use our How to Invest in Champions Oncology guide.

Latest Champions Oncology's Total Revenue Growth Pattern

Below is the plot of the Total Revenue of Champions Oncology over the last few years. Total revenue comprises all receipts Champions Oncology generated from the sale of its products or services. It is the total amount of income generated by the sale of goods or services related to the company's primary operations. Champions Oncology's Total Revenue historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Champions Oncology's overall financial position and show how it may be relating to other accounts over time.
Total Revenue10 Years Trend
Slightly volatile
   Total Revenue   
       Timeline  

Champions Total Revenue Regression Statistics

Arithmetic Mean26,055,183
Geometric Mean18,624,977
Coefficient Of Variation72.36
Mean Deviation16,485,396
Median20,241,000
Standard Deviation18,853,666
Sample Variance355.5T
Range51.7M
R-Value0.97
Mean Square Error25.8T
R-Squared0.93
Slope4,071,519
Total Sum of Squares4976.5T

Champions Total Revenue History

202452.7 M
202350.2 M
202253.9 M
202149.1 M
202041 M
201932.1 M
201827.1 M

About Champions Oncology Financial Statements

Champions Oncology shareholders use historical fundamental indicators, such as Total Revenue, to determine how well the company is positioned to perform in the future. Although Champions Oncology investors may analyze each financial statement separately, they are all interrelated. The changes in Champions Oncology's assets and liabilities, for example, are also reflected in the revenues and expenses on on Champions Oncology's income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
Total Revenue50.2 M52.7 M

Pair Trading with Champions Oncology

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Champions Oncology position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Champions Oncology will appreciate offsetting losses from the drop in the long position's value.

Moving against Champions Stock

  0.4KTTAW Pasithea TherapeuticsPairCorr
The ability to find closely correlated positions to Champions Oncology could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Champions Oncology when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Champions Oncology - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Champions Oncology to buy it.
The correlation of Champions Oncology is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Champions Oncology moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Champions Oncology moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Champions Oncology can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Additional Tools for Champions Stock Analysis

When running Champions Oncology's price analysis, check to measure Champions Oncology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Champions Oncology is operating at the current time. Most of Champions Oncology's value examination focuses on studying past and present price action to predict the probability of Champions Oncology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Champions Oncology's price. Additionally, you may evaluate how the addition of Champions Oncology to your portfolios can decrease your overall portfolio volatility.